[Correspondence] Sotorasib versus docetaxel: evidence supporting CodeBreaK 200

Given the inflammatory title of Sruthi Ranganathan and colleagues’ Perspectives piece,1 we first must defend our patients and co-investigators. We investigators are highly trained physicians with integrity and a deep mission to serve our patients. Such misuse of the term quackery and alarmist tones are irresponsible and contribute to erosion of trust between patients and physicians, a trust which is foundational to clinical research.